Transcode Therapeutics, Inc., The Rna Oncology Company, Announced That It Has Received Written Authorization From The Us Food And Drug Administration (Fda) That It May Proceed With Its First-In-Human (Fih) Phase 0 Clinical Trial. The Planned Clinical Trial Is To Evaluate Transcode
